GlaxoSmithKline (GSK) said results of a recent study showed that Nucala (mepolizumab) is effective in helping certain patients deal with asthma.
The results showed that Nucala helped improve lung function and boost eosinophil levels of patients with severe asthma, GSK said in a release.
The results showed that patients with more than 150 cells per microliter of eosinophils saw their health standard get 7.8 units better, or 95 percent, and patients with more than 300 cells per microliter of eosinophils saw their health standard get 8.2 units better, or 95 percent, the release said. Patients with more than 500 cells per microliter of eosinophils saw their health standard get 7.7 units better, or 95 percent, when compared to a placebo treatment.
The results also showed that patients with more than 150 cells per microliter of eosinophils experienced a 137-milliliter rise in how their lungs worked, patients with more than 300 cells per microliter of eosinophils experienced a 165-milliliter jump in how their lungs worked, and patients with more than 500 cells per microliter of eosinophils experienced a 206-milliliter jump in how their lungs worked compared to placebo treatment, the release said.
"Nucala has the potential to offer meaningful improvements in important clinical endpoints, as well as patient-reported outcomes, in severe asthma patients with blood eosinophil levels of (150 cells per microliter) and above," Dr. Frank Albers, GSK's global medical affairs lead for Nucala, said in the release.
